Pharmaceutical composition for treating obesity

Abstract

The invention discloses a pharmaceutical composition for treating obesity-related diseases. The composition contains a therapeutically-effective amount of 1-isopropyl-1'-(1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-carbonyl)-4,6-dihydrospiro[indazol-5,4'-piperidine]-7(1H)-one and a therapeutically-effective amount of 4-[5-cyano-4-({2-fluoro-4-[(2-hydroxyethyl) sulfonyl]phenoxy}methyl)-1H-pyrazol-1-yl]piperidin-1-isopropyl formate which have the mass ratio of (3: 1) to (1: 3). By using the two kinds of drugs in a combined manner, symptoms, such as hypertension and diabetes, caused by obesity can be treated while the obesity is treated.

Description

technical field [0001] The invention relates to a pharmaceutical composition, in particular to a pharmaceutical composition for treating obesity. Background technique [0002] Obesity is a state of excessive accumulation of body fat, especially triglycerides (triacylglycerols). Usually due to excessive food intake or changes in body metabolism, excessive fat accumulation in the body results in excessive weight gain and pathophysiological changes in the human body. Body mass index (BMI) is the square of weight (Kg) divided by height (m), and is an indicator for assessing the degree of obesity. In Europe and America, BMI≥25kg / m 2 Overweight, BMI≥30kg / m 2 for obesity. People in the Asia-Pacific region can be divided according to their BMI: healthy 18.5-22.9kg / m 2 ;Overweight 23-24.9kg / m 2 ; Level 1 obesity 25-29.9kg / m 2 ;2 degree obesity 30-34.9kg / m 2 ; Grade 3 obesity > 35kg / m 2 . [0003] Obesity can cause high blood pressure (the incidence of obesity is 25-55%),...

AI Technical Summary

Problems solved by technology

[0013] In the prior art, most of the treatment of obesity only considers the obesity itself, but does not consider the accompanying diseases of obesity, such as hypertension, hyperlipidemia, diabetes, etc.